event,time
60 years old,0
    male ,0
    ischemic cardiomyopathy ,0
    admitted for VT storm ,0
    anteroseptal myocardial infarction ,-262080
    thrombolytic medication ,-262080
    left ventricular ejection fraction 17% ,-350400
    subcutaneous implantable cardioverter-defibrillator ,-350400
    VT episodes ,-350400
    ICD therapy ,-350400
    medication adjustments ,-350400
    recurrent VT ,-10560
    unchanged ejection fraction ,-10560
    S-ICD explanted ,-10560
    CRT-D implanted ,-10560
    cardiac MRI scan ,-10560
    LV thrombus ,-10560
    vitamin K antagonist ,-10560
    antero-septal antero-lateral myocardial infarction ,-10560
    admitted to secondary hospital ,-720
    VT storm ,-720
    transferred to academic hospital ,-720
    tertiary referral hospital ,-720
    hypotensive ,-720
    external electrical cardioversions ,-720
    repeat diagnostic work-up ,-720
    high-dose intravenous amiodarone ,-720
    multiple beta-blockers ,-720
    mexiletine ,-720
    quinidine ,-720
    antibiotic therapy ,-720
    septic ,-720
    peripherally inserted central catheter ,-720
    Staphylococcus aureus bacteremia ,-720
    antibiotics adjusted ,-720
    physical examination ,-720
    echocardiography ,-720
    [18F]FDG-PET/CT scan ,-720
    carbohydrate-free diet ,-720
    fasting ,-720
    intravenous heparin ,-720
    no endocarditis ,-720
    continued antibiotics ,-720
    urgent catheter ablation considered ,-720
    apical thrombus ,-720
    anticoagulation therapy ,-720
    unsuitable for procedure ,-720
    high-dose antiarrhythmic drugs ,-720
    200 mg metoprolol ,-720
    400 mg amiodarone ,-720
    600 mg mexiletine ,-720
    VTs recurred ,-720
    sedation ,-720
    intubation ,-720
    antiarrhythmic medication adjustment ,-720
    extubated ,-720
    percutaneous left stellate ganglion blockade ,-720
    VTs recurred ,-720
    hospitalized for more than a month ,-720
    experimental cardiac radioablation considered ,-720
    therapeutic options discussed ,-720
    discontinuation of therapy ,-720
    high-risk catheter ablation ,-720
    compassionate use ,-720
    patient opted for cardiac radioablation ,-720
    written informed consent ,-720
    radioablation targeting guided by AHA Segmented Model ,0
    myocardial scar in anteroseptal segments ,0
    abnormal strain percentages ,0
    9 different VT morphologies ,0
    inferred exit sites ,0
    final target ,0
    clinical target volume 67 cm3 ,0
    internal target volume ,0
    isotropic expansion ,0
    planning target volume 300 cm3 ,0
    dose of 25 Gy ,0
    3-arc VMAT plan ,0
    treated on AgilityTM ,0
    77 sustained VT-episodes ,-720
    37 days hospitalization ,-720
    25 VT requiring electrical cardioversion ,-720
    VT recurred 4 hours post-radioablation ,4
    no further VTs ,4
    transferred back to secondary hospital ,312
    discharged home ,624
    no VT episodes ,624
    COVID-19 infection ,624
    cardiac rehabilitation therapy ,624
    tapering off antiarrhythmic drugs ,624
    no myocardial injury ,24
    hs-Troponin-T unchanged ,24
    echocardiographic ejection fraction unchanged ,24
    electrocardiogram unchanged ,24
    NT-ProBNP reduced 77% ,24
    no pericardial effusion ,24
    nausea ,48
    vomiting ,48
    CTCAE grade 1 ,48
    antiemetic medication ,48
    whole body [18F]FDG-PET/CT scan ,720
    no endocarditis ,720
    extensive 18F-FDG uptake ,720
    LV thrombus evaluation ,720
    therapy-refractory VT storm ,0
    incessant VT ,0
    direct VT-reducing effect ,0
    no acute adverse events ,0
    increased metabolic activity ,0
    no signs of endocarditis ,0
    no myocardial injury ,0
    continued follow-up ,0
    stable cardiac function ,0
    successful recovery ,0
    resumed normal activities ,0
    improved quality of life ,0
